Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

By: via Benzinga
Bluebird Bio Inc(NASDAQ: BLUE) has agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV)for $102 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.